Evidence from large epidemiological and clinical studies indicate that some cRAS-targeting anti-hypertensives, including ACE1 inhibitors (ACE-Is) and AT1R receptor blockers (ARBs), reduce the incidence of AD [7–9], and can prolong the conversion to MCI and delay the onset of dementia [10–12]. Here, ACE is linked to Alzheimer disease.